Investors

Overview

Corporate Profile

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

Press Releases

CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer

With an experienced Chief Financial Officer on board, the company is continuing to advance its fight against cancer. CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a […]

CytoImmune Therapeutics Announces Appointment of Industry Veteran Douglas E. Williams, Ph.D., to Board of Directors

MONROVIA, Calif., June 15, 2021 /PRNewswire/ -- CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today the […]

City of Hope Enters Licensing Agreements with CytoImmune Therapeutics Inc. to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies

License and development agreements will advance several immunotherapies City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications […]

CytoImmune Therapeutics Establishes Operations in Puerto Rico to Develop Novel Cancer Immunotherapy Products

SAN JUAN, Puerto Rico, March 1, 2021 /PRNewswire/ -- Invest Puerto Rico (InvestPR), the Island's economic development organization, and the Puerto Rico Department of Economic Development […]

Invest Puerto Rico elevates the Island’s role as a global bioscience R&D and manufacturing hub attracting two major life-critical investments, $228M in new activity

- CytoImmune Therapeutics and Biosimilar Sciences US will soon call Puerto Rico home and engage in cancer immunotherapy solutions and a COVID-19 vaccine, respectively - Both […]

Events Presentation

CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

Press Releases

Events Presentation

CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]